Oxadel 300 IV Infusion Injection

About Oxadel 300 IV Infusion Injection

Oxadel 300 IV Infusion is made by Square Pharmaceuticals PLC. It is a hospital antibiotic given by intravenous infusion in the strength of 300 mg per vial.

There are 3 brands of Delafloxacin listed in Bangladesh.

What is Oxadel 300 IV Infusion Injection?

Oxadel 300 IV Infusion is an antibiotic from Square Pharmaceuticals PLC. Its active ingredient is delafloxacin, which belongs to the quinolone group of medicines. It works by interfering with the processes bacteria need to copy their genetic material, which helps stop the bacteria from multiplying. Oxadel 300 IV Infusion is supplied as a vial containing 300 mg, and it is given by infusion into a vein, so it is used in a hospital or clinic setting under the care of a doctor. Whether it suits a particular person depends on the infection and on the doctor's assessment.

Uses of Oxadel 300 IV Infusion

Oxadel 300 IV Infusion is used in adults to treat acute bacterial skin and skin structure infections. These are bacterial infections of the skin and the tissues just beneath it. The doctor decides whether this medicine is appropriate after assessing the infection. It is not for viral infections or for infections that are not caused by bacteria, and it should only be used when a doctor has confirmed that an antibiotic of this kind is needed.

How to use Oxadel 300 IV Infusion

Oxadel 300 IV Infusion is given by a healthcare professional as an infusion into a vein; it is not for use at home by the patient. The doctor decides the dose, how fast it is given and how long the course lasts. Tell the doctor or pharmacist about all other medicines you take, because some medicines and supplements can interfere with this type of antibiotic. If you notice any reaction during the infusion, tell the staff straight away.

Side effects of Oxadel 300 IV Infusion

Some people may have side effects while receiving Oxadel 300 IV Infusion. The commonly reported ones are nausea, diarrhoea, headache, vomiting and changes in liver enzyme tests. A skin rash or other sign of an allergic reaction needs urgent attention, and the medicine is stopped if one appears. Diarrhoea that is severe or does not settle should be checked by a doctor. Ask the doctor or pharmacist about anything you notice during or after treatment.

Safety and precautions

Tell the doctor before treatment if you have ever had an allergic reaction to delafloxacin or to any quinolone antibiotic, or if you have other health problems or are taking other medicines. Data on use in pregnancy are limited, and there are no data on use during breastfeeding; the doctor will weigh the benefits and risks for you. Ask the doctor first if you are pregnant, think you may be pregnant, or are breastfeeding. The dose and course are decided only by the doctor.

Frequently asked questions

Is Oxadel 300 IV Infusion safe in pregnancy or breastfeeding?

There are limited data on its use in pregnancy and no data on its use during breastfeeding. Do not decide on your own; tell the doctor if you are pregnant, may be pregnant or are breastfeeding so the benefits and risks can be weighed for you.

What is Oxadel 300 IV Infusion used for and what kind of medicine is it?

It is an antibiotic of the quinolone group. It is used in adults for acute bacterial skin and skin structure infections. The doctor decides whether it is suitable for a particular infection after assessing it.

What does the dosage form and strength mean?

It comes as a vial containing 300 mg of delafloxacin, and it is given as an intravenous infusion into a vein by a healthcare professional. The doctor decides the dose and course; the strength on the vial is the amount the product contains.

Who should not receive Oxadel 300 IV Infusion?

It should not be given to anyone with a known allergy to delafloxacin, to other quinolone antibiotics or to any ingredient of the product. Tell the doctor about any past allergic reaction, other health conditions or medicines you take before treatment.

Indications

Acute Bacterial Skin and Skin Structure Infections: Delafloxacin is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] ... Read moreAcute Bacterial Skin and Skin Structure Infections: Delafloxacin is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, Enterococcus faecalis, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Community-Acquired Bacterial Pneumonia: Delafloxacin is indicated in adults for the treatment of community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible [MSSA] isolates only), Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, Chlamydia pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae.

Usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Delafloxacin and other antibacterial drugs, Delafloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Pharmacology

Delafloxacin inhibits the activity of bacterial DNA topoisomerase IV and DNA gyrase (topoisomerase II). This interferes with bacterial DNA replication by preventing the relaxation of positive supercoils introduced as part of the elongation process. The resultant strain inhibits further elongation. Delafloxacin exerts concentration-dependent bacteriocidal activity.

The antibacterial activity of delafloxacin appears to best correlate with the ratio of area under the concentration-time curve of free delafloxacin to minimal inhibitory concentration (fAUC/MIC) for Gram-positive organisms such as Staphylococcus aureus and Gram-negative organisms such as Escherichia coli based on animal models of infection.

Dosage & Administration

Delafloxacin Tablets: Administer Delafloxacin at least 2 hours before or 6 hours after antacids containing magnesium, or aluminum, with sucralfate, with metal cations such as iron, or with multivitamin preparations containing zinc or iron, or with didanosine buffered tablets for oral suspension or the pediatric powder for oral solution. Delafloxacin Tablets can be taken with or without food. If patients miss a dose, they should take it as soon as possible anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remain before the next dose, wait until their next scheduled dose.

Delafloxacin Injection: Do NOT administer Delafloxacin for Injection with any solution containing multivalent cations, e.g., calcium and magnesium, through the same intravenous line. Do NOT co-infuse Delafloxacin for Injection with other medications. 

Acute bacterial skin and skin structure infections: 300 mg of Delafloxacin for Injection every 12 hours over 60 minutes by intravenous infusion Or 300 mg of Delafloxacin for Injection every 12 hours over 60 minutes by intravenous infusion, then switch to a 450 mg Delafloxacin tablet orally every 12 hours at the discretion of the physician Or 450 mg Delafloxacin tablet orally every 12 hours for 5 to 14 days.

Community-Acquired Bacterial Pneumonia: 300 mg of Delafloxacin for Injection every 12 hours over 60 minutes by intravenous infusion Or 300 mg of Delafloxacin for Injection every 12 hours over 60 minutes by intravenous infusion, then switch to a 450 mg Delafloxacin tablet orally every 12 hours at the discretion of the physician Or 450 mg Delafloxacin tablet orally every 12 hours for 5 to 10 days.

Interaction

Fluoroquinolones form chelates with alkaline earth and transition metal cations. Oral administration of Delafloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of Delafloxacin, resulting in systemic concentrations considerably lower than desired. Therefore, Delafloxacin should be taken at least 2 hours before or 6 hours after these agents. There are no data concerning an interaction of intravenous Delafloxacin with oral antacids, sucralfate, multivitamins, didanosine, or metal cations. However, Delafloxacin should not be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line

Contraindications

Delafloxacin is contraindicated in patients with known hypersensitivity to delafloxacin or any of the fluoroquinolone class of antibacterial drugs, or any of the components of Delafloxacin.

Side Effects

Most common adverse reactions (incidence ≥2%) are nausea, diarrhea, headache, transaminase elevations, and vomiting.

Pregnancy & Lactation

Pregnancy: The limited available data with Delafloxacin use in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriages. When delafloxacin (as the N-methyl glucamine salt) was administered orally to rats during the period of organogenesis, no malformations or fetal death were observed at up to 7 times the estimated clinical exposure based on AUC. When rats were dosed intravenously in late pregnancy and through lactation, there were no adverse effects on offspring at exposures approximating the clinical intravenous (IV) exposure based on AUC.

Lactation: There are no data available on the presence of delafloxacin in human milk, the effects on the breast-fed infant, or the effects on milk production. Delafloxacin is excreted in the breast milk of rats. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Delafloxacin and any potential adverse effects on the breast-fed child from Delafloxacin or from the underlying maternal condition.

Precautions & Warnings

Hypersensitivity Reactions: May occur after first or subsequent doses of Delafloxacin. Discontinue Delafloxacin at the first sign of a skin rash or any other sign of hypersensitivity. Clostridium difficile-associated diarrhea: Evaluate if diarrhea occurs.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Alternative brands of Delafloxacin

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.